奥赛康1月15日获融资买入2015.22万元，融资余额1.30亿元

Core Viewpoint - On January 15, Aosaikang's stock fell by 2.30%, with a trading volume of 202 million yuan, indicating a decline in market performance [1] Financing Summary - On January 15, Aosaikang had a financing buy amount of 20.15 million yuan, with a current financing balance of 130 million yuan, accounting for 0.77% of the circulating market value [2] - The company had a net financing buy of 6.90 million yuan after a repayment of 13.25 million yuan [1][2] - As of January 15, the total margin balance for Aosaikang was 131 million yuan [1] Company Overview - Aosaikang Pharmaceutical Co., Ltd. is located in Jiangning Science Park, Nanjing, Jiangsu Province, established on December 24, 1996, and listed on May 15, 2015 [2] - The company's main business involves the research, production, and sales of drugs, with revenue composition as follows: oncology 38.28%, anti-infection 24.74%, chronic diseases 21.65%, digestive 12.33%, and others 2.34% [2] Financial Performance - For the period from January to September 2025, Aosaikang achieved an operating income of 1.434 billion yuan, representing a year-on-year growth of 3.57% [2] - The net profit attributable to the parent company was 223 million yuan, showing a significant year-on-year increase of 75.81% [2] Dividend Information - Since its A-share listing, Aosaikang has distributed a total of 721 million yuan in dividends, with 111 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Aosaikang had 30,000 shareholders, a decrease of 2.21% from the previous period, with an average of 30,934 circulating shares per person, an increase of 2.26% [2][3] - Notable institutional shareholders include Yongying Medical Innovation Mixed Fund and others, with significant increases in holdings [3]